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As teachers of medical courses and professionals who
work in a challenging environment for public health and
day-to-day clinical decisions, we are concerned about how
up-to-date medical knowledge that is presented in scientific
papers is translated into clinical directives or public health
decisions. To illustrate, we refer to screening for breast,
colon and prostate cancer. The common message that may
be derived from these examples was summed in The New
York Times in 2007 (1), as follows: ‘‘Nobody likes to be at the
mercy of an expert, especially of those who charge for their
services and whose trustworthiness can be hard to assess.
Mechanics are a common source of this frustration, but
there are many others: doctors, plumbers, financial advisers,
real estate agents and technical support people, to name a
few.’’
The three scenarios
In November 2012, Bleyer and Welch described the
limited value of Breast Cancer Screening (BCS) in women
40 years of age or older over the last 30 years (2). The
authors expressed doubts regarding the benefit of BCS but
concluded with the message that BCS is effective.
Subsequently, several letters to the editor were published.
French scientists addressed an important discrepancy in
the results derived from epidemiologic versus randomized
trials (3), i.e. the marginal benefit found in Bleyer and
Welch’s study and in several European epidemiologic
studies contrasts with the clear benefit of mammography
derived from several randomized trials. Colleagues from
the Nordic Cochrane Center emphasized the considerable
harm associated with over-diagnosis of breast cancer and
stated that breast cancer screening should be avoided (4).
Lannin claimed that Bleyer and Welch should have
interpreted their results differently to more clearly
describe the identified marginal benefit of mammography
(5). The Society of Breast Imaging classified the Bleyer and
Welch paper as a flawed analysis (6). This society asserted
that the known 25%-30% reduction in breast cancer
mortality contradicts the results reported by Bleyer and
Welch.
The broad spectrum of interpretations reflects the need
for a new culture of scientific discussion, as expressed by
the authors’ reply to these comments (7). Three important
aspects of the original NEJM paper should be addressed.
First, it clearly showed that the implementation of mammo-
graphy screening increased the annual detection rate of early
breast cancer cases from approximately 120 to 240 cases per
100,000 investigated women (2). In other words, the
detection rate doubled. In absolute numbers, the results
indicated that approximately 80,000 additional women per
year are diagnosed with breast cancer in each of the larger
European countries, including France, Germany, Italy and
the United Kingdom, due to BCS. Second, Bleyer and Welch
showed that late stage disease includes the following two
subgroups of breast cancer patients: those in the regional late
stage, which may be treated effectively, and those in the
distant late stage, which remains quite difficult to treat. Third,
the influence of BCS on the incidence of regional late stage
and distant late stage disease differed. The incidence of
regional late stage disease was increasing prior to the
implementation of screening (and other methods not
discussed here) but has been decreasing since the imple-
mentation of screening. By contrast, the incidence of distant
late stage disease was the same before and after the
implementation of screening and other innovations. From
a critical point of view, screening causes an impressive
effect, i.e. the detection of an additional 120 cases of early
breast cancer per 100,000 women. However, thus far, no
data indicate that this impressive effect adds any measur-
able benefit to the management of breast cancer. In reality,
this impressive effect is used to justify surgery, radiotherapy
and several types of adjuvant therapies but does not lead to
a survival benefit. The benefit observed in regional late
stage disease exists but is not influenced by screening.
Furthermore, the calculated life expectancy of breast cancer
patients has increased since the introduction of screening. It
should be stressed that the same calculated effect can be
demonstrated when a large number of women are diag-
nosed with ‘benign’ breast cancer that will never proceed to
distant late stage disease. By increasing the proportion of
‘benign’ breast cancer cases through more aggressive tests,
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calculated life expectancy will increase even if no treatment
is available for any breast cancer patient. Bleyer and Welch
(2) were accurate in their data presentation and discussion
of harm caused by over-diagnosis; however, they did not
seem to accept that their data showed more harm than the
expected benefit.
The second scenario is related to colon cancer screening,
which is widely recommended by experts (8-11). Most of
these experts claim that existing data confirm a reduction
in mortality from colon cancer due to screening. However,
a detailed analysis of the existing literature demonstrated
that the quality of the reports that support screening for
colon cancer is insufficient to justify the risks of screening
(12).
A third scenario—screening for prostate cancer—also
warrants a critical review. In an e-mail to our group,
Professor Richard J. Ablin recently stated that when he first
described the Prostate Specific Antigen (PSA) approxi-
mately 40 years ago, he never expected that his discovery
would harm millions of men and waste billions of dollars.
His warnings have been rather ineffective (13-15).
The voice of a communication expert
Several years ago, the former editor of British Medical
Journal, Professor Richard Smith, addressed this problem
from the editor’s perspective in a series of articles in which
he stated the following (16,17): ‘‘Medical journals are a
confluence of medicine, science and journalism - and might
be expected to have the values of all three. Sometimes,
however, these values conflict.’’ According to Richard
Smith, we are in an abysmal state, as thousands of
biomedical journals are publishing mediocre research for a
profit. In other words, we all are driven by commerce, i.e.
the need to make a profit. Mediocre research may be
contaminated with fraudulent or spun research.
Smith proposed open access publications and the empha-
sis of ethical and evidence-based practice as solutions to this
problem. We believe that these solutions are the correct
strategies but are not sufficient to change the present
situation. Unless we develop a new way of thinking, we
will not be able to change the direction of the present
development in any society. We are currently driven by
commerce and making a profit for ourselves or for our
companies. This goal and the related attitudes, skills and
knowledge lead to inconvenient long-term effects in health
care.
These long-term effects may occur in the health care
system unless we shift from commercialization to econo-
mization. Economization refers to balancing (monetary and
non-monetary) costs and consequences of alternative
actions. The goal of economization is to identify the optimal
solution for the patient’s health problem. The essential
difference between economization and commercialization is
the target. Although both strive for profit, commercializa-
tion focuses on one’s ‘‘own profit’’ or ‘‘own company
profit’’, whereas economization addresses ‘‘patient profit.’’
This differentiation is applicable to day-to-day practice.
Economic decisions guarantee that the benefit from health
services will be higher for the patient than for any other
player in the system, whereas commercial decisions ensure
that at least one player in the system other than the patient
will benefit most from a particular health service. This
observation leads back to The New York Times article:
‘‘Nobody likes to be at the mercy of an expert …’’ The
distinction between economic and commercial decisions is
not supported by statistical data; rather, it is based on
societal values, which differ across cultures. We conducted a
series of experiments that confirmed that the interpretation
of scientific papers is more influenced by one’s personal
belief regarding long-accepted assumptions than by the
quality of the study design or presented data (18-20).
Possible solution to the problem
The acceptance of a scientific fact can only occur through
extensive discussion with multiple partners. Considering
the pressure on scientists, practitioners and public health
decision makers, it is not sufficient to state that screening
must detect life-threatening disease (2). In the case of
screening programs, we must consider significant conflicts
of interest. Therefore, we must focus on the most reliable
endpoint of screening, reduced mortality. Mortality from
any type of cancer will be reduced only if screening enables
effective treatment that reduces the incidence of life-
threatening disease. As discussed by Bleyer and Welch,
the incidence of life-threatening breast cancer has not been
reduced since 1976. Furthermore, approximately 90% of
diagnosed prostrate cancer is not life-threatening. Finally,
the research on colon cancer is poor and, thus, cannot be
accepted as valid support for the effectiveness of screening.
The good news is that regional advanced breast disease can
be effectively treated; however, these treatments do not
depend on efficient screening methods.
We conclude that these screening programs do not
influence survival but may induce ‘perceived safety’ (21)
in patients who believe that screening is beneficial and
physicians who act in the best interest of the patient.
Angelina Jolie’s recent campaign that advocates for addi-
tional money for breast cancer screening of members of
affected families is associated with a high risk of misman-
agement. Genetic screening can provide information that is
otherwise unavailable; however, the important question is
whether this new information will improve health. Recent
progress in telemedicine will lead to a tremendous increase
in information (22). As most individuals will be able to
generate new health care data, two risks will increase, the
risk of generating more uncertainty than safety and the risk
of dramatically increasing the demand for medical con-
sultations.
The example of telemedicine demonstrates that the
difficulty is likely not confined to medical journals, but
may also extend to opinion leaders in health care. Most of
this trouble is related to conflicts of interest (23). We
typically consider conflicts of interest as unethical relation-
ships between scientists and practitioners and the pharma-
ceutical industry. Conflicts of interest can also emerge from
unprofessional conceptions, uncritical use of medical tests,
the high vulnerability of patient trust and confidence and
the fact the health care services are often provided and
evaluated by the same individuals. Thus, conflicts of interest
are evident throughout health care systems. Consequently,
the future challenge is not avoiding these conflicts of
interest, but addressing them. Transparency and scientific
validity will be the core principles in the management of
conflicts of interest. Progress will not typically emerge from
mainstream viewpoints, but may emerge from a fair
discussion of controversial opinions.
Graduate institutions should teach students how to
develop such controversial opinions by providing the
The true message of scientific papers
Porzsolt F et al.
CLINICS 2013;68(9):1177-1179
1178
opportunity to discuss examples such as cancer screening
and telemedicine in the context of public health decisions.
Because young professionals have less prejudice against
new statements, less incongruity with previously learned
knowledge and fewer conflicts of interest, their perspective
is typically more accurate than that of long-time profes-
sionals.
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